Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000, Ljubljana, Slovenia.
Laboratory of Toxicology, Department of Environmental Science and Policy, University of Milan, Via Balzaretti 9, 20133, Milan, Italy.
Eur J Med Chem. 2020 Mar 15;190:112089. doi: 10.1016/j.ejmech.2020.112089. Epub 2020 Jan 24.
NOD1 and NOD2 are pattern recognition receptors that have important roles in innate immune responses. Although their overactivation has been linked to a number of diseases, NOD2 in particular remains a virtually unexploited target in this respect, with only one structural class of antagonist reported. To gain insight into the structure-activity relationships of NOD2 antagonists, a series of novel analogs was designed and synthesized, and then screened for antagonist activity versus NOD2, and counter-screened versus NOD1. Compounds 32 and 38 were identified as potent and moderately selective NOD2 antagonists, and 33 and 42 as dual NOD1/NOD2 antagonists, with balanced activities against both targets in the low micromolar range. These data enable in-depth exploration of their structure-activity relationships and provide deeper understanding of the structural features required for NOD2 antagonism.
NOD1 和 NOD2 是模式识别受体,在先天免疫反应中具有重要作用。虽然它们的过度激活与许多疾病有关,但 NOD2 在这方面仍然是一个几乎未被开发的靶点,仅报道了一种结构类型的拮抗剂。为了深入了解 NOD2 拮抗剂的结构-活性关系,设计并合成了一系列新型类似物,然后对其针对 NOD2 的拮抗剂活性进行筛选,并针对 NOD1 进行反向筛选。化合物 32 和 38 被鉴定为强效且中度选择性的 NOD2 拮抗剂,而化合物 33 和 42 则为 NOD1/NOD2 双重拮抗剂,对两个靶点的活性在低微摩尔范围内平衡。这些数据使我们能够深入探索它们的结构-活性关系,并深入了解 NOD2 拮抗作用所需的结构特征。